Does Rallies show 13F holders for CRVS?

Yes. Rallies tracks hedge fund and 13F ownership data for CRVS, including fund names, share counts, latest tracked quarter, and position changes when available.

Is CRVS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CRVS. It does not provide personalized investment advice.

CRVS (Corvus Pharmaceuticals, Inc.) Stock Analysis - Hedge Fund Holdings

Corvus Pharmaceuticals, Inc. (CRVS) is a publicly traded Healthcare sector company. As of May 20, 2026, CRVS trades at $12.33 with a market cap of $1.03B and a P/E ratio of -64.19. CRVS moved +5.83% today. Year to date, CRVS is +79.53%; over the trailing twelve months it is +231.25%. Its 52-week range spans $2.54 to $26.95. Analyst consensus is strong buy with an average price target of $31.60. Rallies surfaces CRVS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns CRVS stock?

Hedge funds tracked by Rallies that own CRVS include Orbimed Advisors. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Corvus Pharmaceuticals, Inc..

CRVS Key Metrics

Key financial metrics for CRVS
Metric	Value
Price	$12.33
Market Cap	$1.03B
P/E Ratio	-64.19
EPS	$-0.19
Dividend Yield	0.00%
52-Week High	$26.95
52-Week Low	$2.54
Volume	1.99M
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-15.28M
Gross Margin	0.00%

Top Hedge Funds Holding CRVS

Orbimed Advisors holds 7.17M shares of CRVS, changed +0.00% as of Mar 31, 2026.

Latest CRVS News

Corvus Ends Q1 with $236.7M Cash, Advances Soquelitinib into Phase 2 and 3 Trials — May 7, 2026
Corvus Raises $201M and Reports 72% EASI Reduction in Phase I AD Trial — Jan 23, 2026
Corvus Prices 7.9M-Share Offering at $22.15 to Raise $175M — Jan 23, 2026
Corvus Soquelitinib Achieves 72% EASI Reduction, Plans 200-Patient Phase II AD Trial — Jan 23, 2026
Phase I Data Shows 72% Mean EASI Reduction and Clean Safety Profile for Soquelitinib — Jan 23, 2026

Recent CRVS Insider Trades

MILLER RICHARD A MD bought 5.00K (~$60.25K) on May 18, 2026.
MILLER RICHARD A MD bought 1.93K (~$23.20K) on May 18, 2026.
ORBIMED ADVISORS LLC sold 1.18M (~$4.89M) on Jun 27, 2025.

CRVS Analyst Consensus

5 analysts cover CRVS: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $31.60.

Common questions about CRVS

Who owns CRVS stock?: Hedge funds tracked by Rallies that own CRVS include Orbimed Advisors. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Corvus Pharmaceuticals, Inc..
Does Rallies show 13F holders for CRVS?: Yes. Rallies tracks hedge fund and 13F ownership data for CRVS, including fund names, share counts, latest tracked quarter, and position changes when available.
Is CRVS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CRVS. It does not provide personalized investment advice.